<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">21311112</PMID>
<DateCompleted>
<Year>2011</Year>
<Month>07</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised>
<Year>2011</Year>
<Month>02</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">2040-2058</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>16</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2011</Year>
</PubDate>
</JournalIssue>
<Title>Antiviral therapy</Title>
<ISOAbbreviation>Antivir. Ther. (Lond.)</ISOAbbreviation>
</Journal>
<ArticleTitle>Fucoidan therapy decreases the proviral load in patients with human T-lymphotropic virus type-1-associated neurological disease.</ArticleTitle>
<Pagination>
<MedlinePgn>89-98</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3851/IMP1699</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Human T-lymphotropic virus type-1 (HTLV-1) is a human retrovirus that causes HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukaemia (ATL). A higher viral load in individuals with HTLV-1 infection increases their risk of developing HAM/TSP and ATL. Moreover, the high proviral load is associated with the clinical progression of HAM/TSP. Reduction of the number of HTLV-1-infected cells is therefore crucial for preventing and treating HTLV-1-associated diseases. Recently, fucoidan, a complex sulphated polysaccharide derived from marine seaweed, has been demonstrated to exert inhibitory effects on HTLV-1 infection in vitro. In this study, we examined the in vivo effects of fucoidan on HTLV-1 infection.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">In this single-centre open-label trial, 13 patients with HAM/TSP were treated with 6 g fucoidan daily for 6-13 months. The HTLV-1 proviral DNA load and frequencies of HTLV-1-specific CD8(+) T-cells, natural killer cells, invariant natural killer T-cells and dendritic cells in the peripheral blood were analysed. Furthermore, the in vitro inhibitory effect of fucoidan on cell-to-cell HTLV-1 infection was examined by using luciferase reporter cell assays.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Fucoidan inhibited the cell-to-cell transmission of HTLV-1 in vitro. Furthermore, fucoidan therapy resulted in a 42.4% decrease in the HTLV-1 proviral load without affecting the host immune cells. During the treatment, no exacerbation was observed. Four patients with HAM/TSP developed diarrhoea, which improved immediately after stopping fucoidan administration.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Fucoidan is a new potential therapeutic agent for the prevention and treatment of HTLV-1-associated diseases.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Araya</LastName>
<ForeName>Natsumi</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Molecular Medical Science, Institute of Medical Science, St Marianna University School of Medicine, Kawasaki, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Takahashi</LastName>
<ForeName>Katsunori</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sato</LastName>
<ForeName>Tomoo</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nakamura</LastName>
<ForeName>Tatsufumi</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sawa</LastName>
<ForeName>Chika</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hasegawa</LastName>
<ForeName>Daisuke</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ando</LastName>
<ForeName>Hitoshi</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Aratani</LastName>
<ForeName>Satoko</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yagishita</LastName>
<ForeName>Naoko</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fujii</LastName>
<ForeName>Ryoji</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Oka</LastName>
<ForeName>Hiroshi</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nishioka</LastName>
<ForeName>Kusuki</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nakajima</LastName>
<ForeName>Toshihiro</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mori</LastName>
<ForeName>Naoki</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yamano</LastName>
<ForeName>Yoshihisa</ForeName>
<Initials>Y</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Antivir Ther</MedlineTA>
<NlmUniqueID>9815705</NlmUniqueID>
<ISSNLinking>1359-6535</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011134">Polysaccharides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9072-19-9</RegistryNumber>
<NameOfSubstance UI="C007789">fucoidan</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 1.13.12.-</RegistryNumber>
<NameOfSubstance UI="D008156">Luciferases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018414">CD8-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002452">Cell Count</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004279">DNA, Viral</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003713">Dendritic Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017930">Genes, Reporter</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015368">Human T-lymphotropic virus 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015459">Leukemia-Lymphoma, Adult T-Cell</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008156">Luciferases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055611">Natural Killer T-Cells</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015493">Paraparesis, Tropical Spastic</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011134">Polysaccharides</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011533">Proviruses</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012624">Seaweed</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019562">Viral Load</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2011</Year>
<Month>2</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2011</Year>
<Month>2</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2011</Year>
<Month>7</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">21311112</ArticleId>
<ArticleId IdType="doi">10.3851/IMP1699</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>